RecallCheckr

Serious recall: Injury is possible or has been reported. Take action promptly.

Ascend Laboratories, LLC 2025-07-23 Health serious FDA
Health · FDA · Recall #FDA-D-0534-2025

Rizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only,… Recall

Issued July 23, 2025 · Ascend Laboratories, LLC

In July 2025, Ascend Laboratories, LLC recalled the Rizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only,…, a serious health recall reported by the FDA.

Compiled by Maya Ellison, RecallCheckr

What this means for you

CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

What you should do

  1. 1 Stop using Rizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only,… right away.
  2. 2 Set it aside where it won't be used by mistake.
  3. 3 Contact Ascend Laboratories, LLC to arrange your voluntary. See the official notice below for contact details.
  4. 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):

Recall details

Brand
Ascend Laboratories, LLC
Category
Health
Recall date
July 23, 2025
Units affected
Not reported
Sold at
US Nationwide.
Recall number
FDA-D-0534-2025
Made in
United States
Issuing agency
FDA

In context

  • Ascend Laboratories, LLC has 12 recalls in our database.
  • We're tracking 3,576 Health recalls in our database.
  • This is the 691st Health recall we've logged in 2025.
Read the official FDA notice

Related recalls